55results about How to "Good neutralizing activity" patented technology

The invention provides an antibody targeting SARS-CoV-2 and a preparation method and application thereof. The antibody comprises VH and VL, wherein the VH comprises the following CDRs: VH CDR1, VH CDR2 and VH CDR3 with amino acid sequences as shown in SEQ ID NO: 1, 2 and 3; the VL comprises the following CDRs: VL CDR1, VL CDR2 and VL CDR3 with amino acid sequences as shown in SEQ ID NO: 4, 5 and 6. The antibody can be highly compatible and specifically combined with RBD of S proteins of SARS-CoV-2, inhibits combination of the RBD protein and receptor ACE2 protein, efficiently inhibits SARS-CoV-2 from infecting cells, and has very good neutralizing activity on potential pseudoviruses of immune escape mutation, so that the antibody can be effectively applied to diagnosis, prevention and treatment of SARS-CoV-2 viruses and related diseases.

The invention relates to the technical field of immunology and molecular virology, and particularly discloses a monoclonal antibody of novel coronavirus and a mutant thereof and application of the monoclonal antibody. Complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or an antigen binding fragment thereof respectively have amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; and complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment thereof respectively have amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. The monoclonal antibody disclosed by the invention can be combined with the S protein RBD of the novel coronavirus and various mutant strains thereof with high affinity, is strong in neutralizing activity, and has ideal clinical application value for preventing and treating infection of the novel coronavirus and various mutant strains thereof.

The invention discloses a neutralizing human monoclonal antibody aiming at a novel coronavirus. The antibody can specifically recognize a novel coronavirus antigen and has better neutralizing activity on a live virus. The epitope directed by the gene is mainly a receptor binding domain of a novel coronavirus. In addition, the antibody disclosed by the invention can be prepared into an antibody drug for preventing and treating the novel coronavirus, so that the antibody drug is clinically used for preventing and treating diseases caused by infection of the novel coronavirus.

The invention belongs to the technical field of biomedicine, and relates to a Clostridium difficile exotoxin A carboxy-terminal gene fragment with an optimized codon and a nucleic acid vaccine thereof. In the gene sequence with the optimized codon, the codon usage biases of mammalian cells and Escherichia coli are considered; and the Clostridium difficile vaccine consists of the exotoxin A carboxy-terminal gene sequence with the optimized codon and a eukaryotic expression vector pJW4303. The Clostridium difficile exotoxin A carboxy-terminal gene fragment with the optimized codon can be used for constructing the nucleic acid vaccine, effectively stimulates an immune system of a host after a mammal is immunized so as to produce better humoral immune response, is also applicable to the prokaryotic expression of a protein in the Escherichia coli, and lays a foundation for the batch acquisition of the protein.

The invention provides an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and an application thereof. The anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), and (a) the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, and (b) the amino acid sequence of CDR-H2 is as shown in SEQ ID NO: 2; (c) the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3; (d) the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4; (e) the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5; and the amino acid sequence of the (f) CDR-L3 is as shown in SEQ ID NO: 6. Compared with an anti-human TSLP monoclonal antibody Tezepelumab (prepared according to sequence expression disclosed in the patent), the anti-human TSLP monoclonal antibody has the advantages that the affinity of the anti-human TSLP monoclonal antibody combined with the human TSLP is equivalent, the neutralizing activity of the anti-human TSLP monoclonal antibody at the cellular level is superior to that of the Tezepelumab, and the anti-human TSLP monoclonal antibody is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

The invention relates to a novel human monoclonal antibody of coronavirus and application of the novel human monoclonal antibody. The antibody can be specifically combined with the 2019-nCoV RBD, the combination of the 2019-nCoV RBD and ACE2 is blocked, and the infection of the 2019-nCoV is inhibited.

The invention provides a neutralizing antibody against novel coronavirus receptor binding regions and application thereof, and belongs to the technical field of biological products. The neutralizing antibody comprises a heavy chain variable region and a light chain variable region; and the heavy chain variable region comprises a heavy chain CDR3 as shown in SEQ ID NO: 3 or SEQ ID NO: 13, and the light chain variable region comprises a light chain CDR3 as shown in SEQ ID NO: 6 or SEQ ID NO: 16. According to the neutralizing antibody against the novel coronavirus receptor binding regions and the application thereof, the neutralizing antibodies C14646P3S and C2767P3S of the SARS-CoV-2 receptor binding region are obtained by utilizing LIBRA-seq high-throughput screening; and the neutralizing antibodies C14646P3S and C2767P3S have relatively strong neutralizing capability on SARS-CoV-2 pseudoviruses and live viruses in vitro, can well block the binding of a novel coronavirus receptor binding region and a receptor thereof, and have important application value in the aspects of prevention, treatment and diagnosis of SARS-CoV-2 infection.

The invention relates to an anti-H7N9 whole-human monoclonal antibody 9I17 and a preparation method therefor and application of the anti-H7N9 whole-human monoclonal antibody 9I17. The whole-human monoclonal antibody 9I17 is quickly screened by utilizing a memory B cell polymerase chain reaction (PCR) method, and does not include any murine component. The antibody disclosed by the invention can bebound to hemagglutinin HA of an H7N9 virus in a targeted manner, and has significant neutralizing activity of anti-H7N9 virus infection; and the antibody disclosed by the invention does not have toxicand side effects of anti-mouse anti-antibodies and the like, has better biocompatibility, and is more suitable and has more potential to become a macromolecular drug for treatment of influenza viruses.

The present invention generally relates to anti-rabies antibodies that can bind to and neutralize rabies virus. The antibodies of the invention are used alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.

The present invention provides an antibody targeting SARS-CoV-2 and its preparation method and application. The antibody comprises VH and VL, and the VH comprises the following CDRs: VH with amino acid sequence as shown in SEQ ID NO: 1, 2, 3 CDR1, VH CDR2, VH CDR3; the VL comprises the following CDRs: VL CDR1, VL CDR2, VL CDR3 with amino acid sequences as shown in SEQ ID NO: 4, 5, 6. The antibody can bind with high affinity and specificity to the RBD of the S protein of SARS-CoV-2, inhibit the binding of the RBD protein to the receptor ACE2 protein, and efficiently inhibit SARS-CoV-2 from infecting cells, while preventing potential immune escape mutations The pseudovirus has good neutralizing activity, so it can be effectively applied to the diagnosis, prevention and treatment of SARS-CoV-2 virus and related diseases.

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

The invention relates to an anti-H7N9 fully human monoclonal antibody 8D11 and its preparation method and application. The fully human monoclonal antibody 8D11 was rapidly screened by memory B cell PCR method without any mouse components. The antibody of the present invention can target the hemagglutinin HA of H7N9 virus, and has a significant neutralizing activity against H7N9 virus infection; the antibody of the present invention does not produce toxic and side effects such as anti-mouse anti-antibody, has better biocompatibility, and is more It is suitable and has more potential to become a macromolecular drug for treating influenza virus.

This application relates to the anti-H7N9 fully human monoclonal antibody 4E18 and its preparation method and application. A fully human monoclonal antibody 4E18 was rapidly screened by memory B cell PCR without any mouse components. The antibody of the present application can target the hemagglutinin HA of the H7N9 virus, and has a significant neutralizing activity against H7N9 virus infection; the antibody of the present application does not cause toxic and side effects such as anti-mouse anti-antibody, has better biocompatibility, and is more It is suitable and has more potential to become a macromolecular drug for treating influenza virus.